Scores are particularly densely packed between Sanofi in seventh place and Gilead in 13th place. This group has similar scores but for very different reasons; the strengths and weakness are diverse, with each company choosing to focus its efforts more or less in different areas the Index measures. With scores this close, comparatively small shifts in performance can trigger a significant rise or fall in rank.
Following closely behind are Boehringer Ingelheim and Bristol-Myers Squibb, in 14th and 15th place respectively. Boehringer Ingelheim has this year pulled out of the lower rankings of the Index with a strengthened access strategy but is held back by a comparatively poor performance in attaching access plans to products in their pipeline.